CD274 and non-small cell lung carcinoma: Moreover, some studies suggest that neoadjuvant nivolumab in combination with ipilimumab improves the primary pathological response in early-stage NSCLC, regardless of PD-L1 expression, suggesting, that dual-ICI offered long-term survival benefits (37–39).